Cagrilintide

What it is

Cagrilintide is an engineered, long-acting analog of amylin — a hormone your pancreas naturally co-releases with insulin every time you eat. Endogenous amylin’s job is to tell your brain you’re full. The problem with endogenous amylin: it breaks down within minutes. By the time you’ve cleared the dishes from a big meal, it’s already gone.

Cagrilintide is amylin re-engineered for pharmacological use. The molecule has been modified with an N-terminal lipid chain that binds albumin in your bloodstream, dramatically extending its half-life from minutes to about a week — which is why you only inject once per week.

The biological inspiration is the same as semaglutide → GLP-1 or tirzepatide → GLP-1 + GIP: take a hormone your body already produces, modify it to last longer, deliver it at therapeutic doses. The difference is that cagrilintide targets the amylin receptor, which is a completely separate pathway from anything in the GLP-1 / GIP / glucagon family. That’s the key to understanding why it stacks.

How it works

The amylin pathway is one of those things most peptide content glosses over — partly because it’s newer in the clinical pipeline, partly because the mechanism story is less viral than “GLP-1 makes you feel full.” Here’s the real picture.

The amylin signaling cycle (and why it breaks down)

When your pancreas releases insulin in response to a meal, it also co-releases amylin. Amylin travels through the bloodstream to your brain, where it binds amylin receptors in the brainstem — specifically the area postrema. The area postrema is part of your “interoceptive” satiety system: it monitors immediate gut signals (stomach distension, nutrient sensing) and tells you when to put the fork down mid-meal.

This system works fine when metabolic health is intact. But as insulin resistance develops, the system breaks in a specific way:

1. Insulin resistance → your pancreas compensates by pumping out more insulin to keep blood sugar in range.
2. More insulin → more amylin co-released alongside it.
3. Chronic high amylin → amylin receptors in the brainstem downregulate (lose sensitivity over time, just like insulin receptors do under chronic insulin exposure).
4. Downregulated amylin receptors → the satiety signal is being broadcast louder than ever, but the receivers have stopped listening.

The customer-side experience: it feels impossible to stop eating once you start. You think it’s willpower. It’s actually a physiological signal failure. The “stop eating” message is being sent — your worn-out receptors just aren’t responding to it strongly enough anymore.

Cagrilintide is essentially a louder, longer-lasting version of the same signal — designed to be powerful enough to break through the receptor downregulation. Worn-out receptors that have stopped responding to endogenous amylin can still respond to cagrilintide because the signal is stronger and persists for days instead of minutes. [ESTABLISHED — textbook amylin physiology + Lau 2021 Lancet pharmacology section]

The “two-receptor-systems” mechanism story (why cagrilintide pairs with GLP-1 drugs)

This is the part that matters for stacking decisions. GLP-1 and amylin operate on completely different parts of the brain:

• GLP-1 receptors sit in the hypothalamus — the “appetite thermostat.” This is the part of your brain that manages baseline drive to seek food: how often you think about food during the day, how strong your cravings are, how much “food noise” you experience between meals. Drugs in the semaglutide / tirzepatide / retatrutide family act here.
• Amylin receptors sit in the brainstem (area postrema) — the “satiety switch.” This is the part of your brain that manages mid-meal satiety: how quickly you feel full, how distinct the signal is to stop eating. Cagrilintide acts here.

The neurons that respond to amylin do not have GLP-1 receptors on them. They’re physically separate cell populations in different brain regions. That’s why cagrilintide is genuinely additive to a GLP-1 drug instead of just stacking on the same pathway: it controls a different aspect of eating behavior using a different cellular circuit.

The simple frame: GLP-1 controls how much you want to start eating; amylin controls when to stop once you’ve started. If you’re on a GLP-1 drug and you still find yourself eating past fullness — that’s the gap cagrilintide fills. If you’re not on a GLP-1 drug at all but want appetite work without the GLP-1 drug class — cagrilintide can stand on its own.

What the research shows

The published RCT base is genuinely strong by peptide-cluster standards — substantially stronger than most of the peptides OHM covers, in fact. Seven peer-reviewed papers anchor the evidence base (one Phase 1b combination, two Phase 2, two Phase 3, one mechanism paper, one systematic review/meta-analysis), with the canonical inventory captured in. Plus nine registered ClinicalTrials.gov entries, four completed and published, five active (including a muscle-health-specific study directly relevant to the protein-priority section below).

The five most load-bearing trials, in chronological order:

Enebo et al. 2021 Lancet — Phase 1b combination PK/PD/safety

The first published trial of cagrilintide combined with semaglutide. This Phase 1b paper established the pharmacokinetic / pharmacodynamic / safety profile of co-administering cagrilintide with semaglutide 2.4 mg — the foundation that all subsequent CagriSema combination work (Frias 2023 Phase 2, REDEFINE 1+2 Phase 3) builds on. The trial demonstrated that the combination was tolerable, with PK profiles supporting once-weekly dosing of both molecules. Not a weight-loss-outcomes trial — its purpose was to clear the PK/PD bar before the Phase 2 efficacy trials.

Lau et al. 2021 Lancet — cagrilintide monotherapy Phase 2 dose-finding

The first major published trial. 706 adults with overweight or obesity (without type 2 diabetes), 57 sites, 26 weeks, double-blind, placebo-controlled, with an active comparator arm.

Design: participants randomized to one of seven cagrilintide doses (0.3, 0.6, 1.2, 1.8, 2.4, 3.0, 4.5 mg once weekly), or placebo, or liraglutide 3.0 mg daily (the GLP-1 comparator).

Key results:

• Clear dose-response curve for cagrilintide monotherapy: weight loss ranged from ~6.0% at the lowest cagrilintide dose to 10.8% at the 4.5 mg top dose, vs 3.0% with placebo.
• The 4.5 mg cagrilintide arm outperformed liraglutide 3.0 mg (10.8% vs 9.0%) — meaningful because liraglutide is an established GLP-1 drug with its own track record.
• GI side effects (mostly nausea) showed up at all cagrilintide doses but were manageable with the titration protocol.

Important context the wiki should hold honestly: Holyfield’s video presents 2.4 mg as the maintenance dose, but the Lau trial’s top arm was 4.5 mg. Practitioner-camp practice has settled lower (2.4 mg matches the CagriSema combination product dose) because the marginal weight-loss benefit at higher doses is offset by more GI side effects. The 2.4 mg dose is a practical compromise; users tolerating titration well sometimes push higher.

Frias et al. 2023 Lancet — Phase 2 CagriSema in type 2 diabetes (the bridge paper)

The Phase 2 trial that bridged monotherapy (Lau 2021) and the Phase 3 combination (REDEFINE 1+2). 17 US sites; adults with type 2 diabetes; tested CagriSema (2.4 mg cagri + 2.4 mg sema once-weekly) against semaglutide-alone and cagrilintide-alone as active comparators.

Headline finding: CagriSema produced significantly greater weight loss than either semaglutide-alone or cagrilintide-alone, with a safety profile that supported moving to longer and larger Phase 3 trials. This is the paper that justified Novo Nordisk’s investment in REDEFINE 1 + REDEFINE 2 — first efficacy + safety data for the combination specifically in T2D patients, where the metabolic dysregulation usually blunts weight-loss interventions.

REDEFINE 1 — CagriSema (cagrilintide + semaglutide) Phase 3

The bigger, more recent, and more clinically decisive trial. 3,417 adults with overweight or obesity (BMI ≥30 kg/m², or ≥27 with at least one obesity-related complication; no T2D in this arm), randomized to one of four groups:

• CagriSema — 2.4 mg cagrilintide + 2.4 mg semaglutide once weekly
• Semaglutide alone — 2.4 mg once weekly
• Cagrilintide alone — 2.4 mg once weekly
• Placebo

68 weeks of treatment plus lifestyle interventions. Headline results:

Full four-arm breakdown — mean body weight change at week 68:

Arm	Weight loss	What this tells us
CagriSema (2.4mg cagri + 2.4mg sema)	-20.4%	The headline combination outcome
Semaglutide-alone (2.4mg)	-14.9%	Matches the established sema monotherapy benchmark
Cagrilintide-alone (2.4mg)	-11.5%	The standalone cagri benchmark in a Phase 3 head-to-head — meaningfully less than sema-alone but real, and well above placebo
Placebo	-3.0%	The control arm

• 22.7% mean weight loss for CagriSema in the placebo-adjusted figure (vs the -20.4% raw-from-baseline)
• 60% of CagriSema participants achieved ≥20% weight loss
• 23% of CagriSema participants achieved ≥30% weight loss — a magnitude historically only seen with bariatric surgery
• 31.6% of cagrilintide-monotherapy participants achieved >15% weight loss (vs 4.7% of placebo arm) — useful standalone-cagrilintide efficacy benchmark for the customer asking “what does cagri-alone actually do?”
• 87.7% of prediabetic participants returned to normoglycemia — major cardiometabolic signal
• Significant improvements in systolic blood pressure, waist circumference, lipid levels, glycemic control
• Randomization ratio: 21:3:3:7 (CagriSema : sema : cagri : placebo)

REDEFINE 2 — Phase 3 CagriSema in T2D + overweight/obesity (NEJM 2025)

The companion trial to REDEFINE 1, tested CagriSema in adults who have BOTH overweight/obesity AND type 2 diabetes — a population where weight-loss interventions have historically delivered smaller magnitudes than in non-diabetic populations (because metabolic dysregulation in T2D blunts the response).

• 1,206 adults with T2D + overweight/obesity, randomized 3:1 to CagriSema (904 patients) or placebo (302 patients), 68 weeks
• CagriSema: -13.7% mean body weight change vs Placebo: -3.4% — meaningful magnitude in a T2D population, smaller than the REDEFINE 1 non-T2D obesity outcome (as expected)
• HbA1c ≤6.5% achieved by 73.5% of CagriSema vs 15.9% of placebo — major glycemic-control signal; for many T2D patients, this is “remission territory”
• Safety profile consistent with GLP-1 receptor agonists; primarily GI AEs (nausea ~55%); discontinuation rates 6–8.4%
• ClinicalTrials.gov: NCT05394519

Why this matters for OHM customers: the published Phase 3 evidence base for CagriSema spans BOTH the non-T2D obesity population (REDEFINE 1) AND the T2D population (REDEFINE 2). Once Novo Nordisk’s FDA filing review completes in 2026, CagriSema is positioned to be approved for both populations simultaneously. For OHM customers, the regulatory clarity matters: post-approval, the brand-name CagriSema becomes a real-world option (with brand-name pricing); the research-use-only verified-vendor compounded route remains the cost-effective access point until then.

The honest gap — cagrilintide + retatrutide has NOT been clinically tested

This is the most important distinction in the entire cagrilintide content space, and many vendors and creators gloss over it. The published combination trial is CagriSema (cagrilintide + semaglutide), not cagri + reta. Stacking cagrilintide on top of retatrutide is mechanistically defensible but clinically untested.

Why the mechanism case is sound: retatrutide activates GLP-1 / GIP / glucagon receptors. Cagrilintide activates amylin receptors. No overlap. Adding cagrilintide to a retatrutide protocol is genuinely adding a new pathway, not doubling up on an existing one. That’s structurally different from (and meaningfully safer than) stacking two GLP-1 drugs together (e.g., semaglutide + retatrutide), which Holyfield correctly flags as a problematic doubling-up that the practitioner camp generally cautions against.

Why the evidence gap matters anyway: real-world dosing, side-effect profiles, and outcome magnitudes in a cagri + reta stack haven’t been measured in a controlled trial. Practitioner-camp adoption appears to be growing (the appearance of pre-mixed cagri + reta blends at peptide vendors signals demand), but the practitioner-camp adoption is not the same as published evidence. OHM’s editorial position is to surface both honestly: the mechanism case AND the evidence gap. Adopt the stack with that gap in mind, not in ignorance of it.

One important correction to the retatrutide mechanism story

Holyfield’s video framed retatrutide as “9× more potent at GIP, only 40% as potent at GLP-1, full activation at glucagon.” The first two are roughly right; the glucagon framing needs a correction.

Per the foundational retatrutide pharmacology paper ([ESTABLISHED — Coskun et al. 2022, *Cell Metabolism*, PMID 35985340]), the actual in vitro receptor potencies (relative to endogenous ligands):

• Glucagon receptor (GCG): 0.3× endogenous — i.e., retatrutide is less potent at the glucagon receptor than endogenous glucagon is.
• GLP-1 receptor: 0.4× endogenous — matches Holyfield’s “40%” framing.
• GIP receptor: 8.9× endogenous — matches Holyfield’s “9×” framing.

The mechanism story still works in vivo (retatrutide does drive hepatic fat oxidation through the glucagon arm), but the in vitro potency at GCG is sub-endogenous, not “full activation.” The wiki holds the corrected version.

Carvas et al. 2025 eBioMedicine — mechanism paper identifies the specific amylin receptors + the lean-mass-preservation finding

The most important mechanism paper published since the CagriSema Phase 3 results. Three findings that materially change how we describe cagrilintide:

1. Cagrilintide’s weight-loss effect depends on AMY1R AND AMY3R amylin receptors specifically. Mouse studies with RAMP1 and RAMP3 knockouts (which prevent functional AMY1R / AMY3R assembly) showed the cagrilintide weight-loss effect is abolished in the knockouts. Wild-type cagrilintide-treated mice lost weight (−3.4 ± 0.51 g, P < 0.005); knockouts didn’t. This identifies the specific receptor subtypes cagrilintide binds — previously the “amylin receptor” framing was generic; this paper resolves to AMY1R + AMY3R.

2. Cagrilintide reduces body weight by REDUCING RELATIVE FAT MASS WHILE MAINTAINING RELATIVE LEAN MASS. This is a mechanism-level confirmation of the body-composition outcome OHM customers care most about — the kind of weight lost matters as much as the magnitude. The animal data shows the molecule itself biases the loss toward fat rather than muscle (in mice). The protein-priority + resistance-training discipline OHM emphasizes (see the safety section below) is what’s needed to RECREATE this lean-mass-preservation pattern in humans where dietary protein intake and resistance training make a much larger difference than they do in lab mice on a fixed diet.

3. Cagrilintide activates cFos signaling in neurons of the dorsal vagal complex and lateral parabrachial nucleus — these are the specific brainstem circuits the wiki’s “satiety switch” framing references. The Carvas paper resolves “brainstem area postrema” into specific neural circuits.

Greenway-Maaløe et al. 2024 — systematic review + meta-analysis

[META-ANALYSIS — PMC11642503]

Published systematic review and meta-analysis of cagrilintide alone and CagriSema as anti-obesity medications. Key findings: CagriSema outperforms semaglutide for weight loss across the pooled trial data; GI adverse events (nausea, vomiting) are significantly higher with CagriSema than with semaglutide alone — quantifies the tolerability trade-off honestly. Useful citable reference for the comparison/stacking section and the GI side-effects framing.

Ongoing studies worth watching (active, not yet published)

Five trials are currently active that could reshape the cagrilintide content over the next 12–36 months. Two are directly relevant to OHM customer questions:

NCT ID	What it tests	Why it matters
NCT07527195	Effect of CagriSema, cagrilintide, and semaglutide on muscle health (role of amylin signature in muscle health)	🔥 Directly tests the muscle-preservation hypothesis the Carvas 2025 animal data suggested. Estimated completion June 2028. If the human muscle-health data replicates the animal lean-mass-preservation finding, that materially strengthens the case for amylin-pathway drugs as the muscle-friendly metabolic-cluster option.
NCT07607587	Tolerability of cagrilintide in patients who don’t tolerate GLP-1-RA therapies due to GI adverse events	Tests whether cagrilintide-alone is a viable alternative for the customer profile that’s been failed by semaglutide/tirzepatide first-line therapy. Commercially significant niche.
NCT06403761	CagriSema, semaglutide, cagrilintide insulin-effects mechanism in T2D	Resolves how much of CagriSema’s glycemic benefit comes from cagrilintide vs semaglutide.
NCT07220642	Weight loss following cagrilintide treatment	Longer-term standalone cagrilintide efficacy in obesity (follow-up to Lau 2021).
NCT07220759	Cagrilintide monotherapy in T2D + overweight/obesity	Standalone cagrilintide-in-T2D — complements the REDEFINE 2 combination data with a monotherapy comparator.

Plus Novo Nordisk’s NN9388-7864 trial (CagriSema vs placebo in T2D + painful diabetic peripheral neuropathy) — exploring expansion into the diabetic-complications space, suggesting Novo sees CagriSema as more than a weight-loss-only drug.

Regulatory: FDA review expected 2026

Novo Nordisk has filed for FDA approval of CagriSema (the combination product) based on the REDEFINE 1 + REDEFINE 2 Phase 3 results. FDA review is expected to conclude in 2026. Once approved, CagriSema becomes a brand-name pharmaceutical available through standard pharmacy channels. Cagrilintide-alone is NOT separately filed; Novo’s commercial path is the combination product, not the monotherapy. For OHM customers: the research-use-only verified-vendor compounded route remains the cost-effective access point for both the combination and the monotherapy until/unless brand-name pricing makes the FDA-approved CagriSema accessible.

Real-world protocol

The doses and schedules below are for educational and informational purposes only. Cagrilintide is sold for research use only and is not FDA-approved as a standalone product. This is not medical advice. Consult a qualified physician before beginning any protocol.

Standard titration (slow ramp to minimize GI side effects)

The practitioner-camp consensus titration matches the Phase 3 CagriSema trial schedule, adapted for cagrilintide-alone or cagri + GLP-1-drug combinations:

Weeks	Cagrilintide dose	Notes
1–4	0.25 mg (250 mcg) weekly SC	Starting dose; nausea + early GI side effects most common here
5–8	0.5 mg weekly SC	First step up — hold here longer if nausea persists
9–12	1.0 mg weekly SC
13–16	1.7 mg weekly SC
17+	2.4 mg weekly SC (maintenance)	The Phase 3 maintenance dose; matches CagriSema combo

Same day each week. Subcutaneous injection (insulin syringe; abdominal or thigh sites are typical).

If side effects are strong at any step, hold at that dose for an additional 4 weeks before stepping up. The titration is more about tolerability than efficacy: many users get good results at lower maintenance doses (0.5–1.0 mg) and don’t need to push to 2.4 mg. The right dose is the lowest dose that delivers the satiety effect you want.

Low-dose responder data point (real-world). Creator-tier reports include cases where 0.25 mg weekly proved fully sufficient as a maintenance dose — strong appetite suppression and clean food-noise reduction, without the over-suppression that can happen at higher doses. One reported case: starting at 1 mg (which is actually the week-9 titration dose, not the recommended week-1 starting dose) produced over-suppression so severe the user couldn’t hit macro targets on training days and reported “no appetite even after the hardest workout of the week” — a red flag. Dropping back to 0.25 mg restored adequate eating capacity while still killing the food noise. Lesson: titrate to the lowest dose that delivers the satiety effect you want. Higher doses (1.0, 1.7, 2.4 mg) are needs-based, not protocol-driven. If 0.25 or 0.5 mg is working, stay there.

GI side-effect mitigation

The standard practitioner-camp playbook for nausea/GI during titration:

• Smaller, more frequent meals during titration weeks (especially weeks 1–4)
• Avoid greasy, fried, or spicy foods early on
• Ginger tea, peppermint, or over-the-counter nausea remedies as needed
• Hydration — GLP-1 / amylin drugs blunt thirst signaling along with hunger signaling, and dehydration amplifies nausea
• If nausea is persistent past the standard step-up holds, drop back a step and re-attempt the ramp slower

Combining with retatrutide (or semaglutide / tirzepatide)

• Always separate injections. Cagrilintide and retatrutide (or any other GLP-1 drug) should be injected separately, not mixed in the same syringe — there’s no published compatibility data on co-formulation outside the brand-name CagriSema product.
• Different injection sites are fine same day, or different days altogether.
• Start cagrilintide titration AFTER you’re stable on your GLP-1 drug, not simultaneously — the combined ramp-up GI side effects are harder to attribute and manage if you start both at once.
• Re-evaluate at maintenance: if the combination produces stronger appetite suppression than you want (some users find it too strong), the right move is usually to dial cagrilintide back rather than dropping it entirely.

Side effects, safety, and the protein-priority warning

GI side effects (expected, manageable)

The dominant side effects during titration are nausea, occasional vomiting, decreased appetite, sometimes mild abdominal discomfort, notable gas in some users (slowed gastric emptying → altered fermentation/microbiome patterns), or altered stool patterns. These match the pattern of any GLP-1 / amylin drug: appetite-suppressing peptides slow gastric emptying as part of their satiety mechanism, and the slowed emptying drives the GI symptoms. Slow titration + dietary adjustments handle most of it. Persistent severe GI symptoms warrant medical consultation, not “push through it.”

Anecdotal mood-change cluster (creator-reported, not RCT-confirmed)

A small number of creator-tier sources have reported mood changes during the first 1–2 weeks of cagrilintide use — low energy, fatigue, mild depressive symptoms — particularly at higher starting doses (1 mg or above). The published RCT data — Lau et al. 2021 Lancet Phase 2 and REDEFINE 1 NEJM 2025 Phase 3 — did NOT report significant mood disturbances or psychiatric adverse events as a confirmed signal. Psychiatric monitoring continues in ongoing studies as standard FDA precaution for weight-management drugs, but no published trial-level signal has emerged.

The published amylin neuroscience literature shows amylin’s primary anorectic mechanism is histaminergic, not serotonergic — and animal studies actually suggest amylin has anxiolytic-like effects on validated behavioral tests rather than depressive-like effects. So the “amylin → serotonin dip → mood change” mechanism story sometimes circulated in creator-space doesn’t match established neuroscience.

Honest take: the anecdotal reports are real signal worth knowing about; the proposed mechanism is not validated; the published trials don’t confirm it. Precautionary guidance: if you have a history of mood disorder, or you’ve experienced mood changes on semaglutide, start at the lowest titration dose (0.25 mg weekly) and track mood carefully during the first 2–3 weeks. If you notice meaningful mood changes that don’t resolve as you adapt to the protocol, pull the dose down or pause and re-evaluate with your prescriber.

The downstream safety issue: muscle loss from undereating

This is the load-bearing safety message OHM customers need to hear, and most cagrilintide content glosses it. Strong appetite suppression feels like winning — the scale moves fast, hunger is gone, you think the protocol is working perfectly. It can also be the setup for the worst medium-term outcome.

The failure mode pattern most users don’t see coming:

• Weeks 1–4: Scale drops fast. You feel in control. You think the peptide is doing all the work.
• Months 2–3: Strength starts dropping. Clothes fit weird — looser on the arms and chest but not as flattering as you’d expect. You’re losing weight but losing the wrong weight.
• Long term: You’ve ended up “skinny fat” — same body fat percentage as before, less muscle, slower resting metabolism. Weight regain when you eventually come off the peptide is faster than it would have been if you’d preserved muscle. You did all the work and didn’t end up looking or feeling the way you wanted.

The cause is mechanical: cagrilintide (especially combined with retatrutide or another GLP-1 drug) cuts your appetite hard enough that you naturally undereat — including protein. Without adequate protein intake, your body breaks down muscle for amino acids to meet its needs. The peptide doesn’t know which tissue to spare; it just suppresses your hunger.

The OHM rule for anyone on cagrilintide (with or without a GLP-1 drug stacked on top):

• 1 gram of protein per pound of body weight, every single day. This is the practitioner-camp consensus and the foundation-first OHM editorial position.
• Protein at every meal — front-load the first meal of the day to anchor the daily total.
• Track it; don’t guess. A free macro-tracking app for the first month is non-negotiable. Most people who think they’re hitting protein targets are off by 30–40%.
• Resistance training is mandatory, not optional. Three sessions per week minimum. The peptide creates a caloric deficit; resistance training tells your body to preserve muscle during that deficit. Without resistance training, the muscle-loss risk multiplies.

This warning isn’t about discouraging cagrilintide use. It’s about ensuring that the customer who does use it ends up with the body composition they actually want — leaner with preserved muscle — instead of “skinny fat” with worse long-term metabolism.

Other safety considerations

• Pregnancy / breastfeeding: Not recommended. No published safety data.
• Type 1 diabetes: Limited published data; consult an endocrinologist before use.
• History of pancreatitis: Caution warranted; amylin and GLP-1 drugs both have signals (though weak) for pancreatitis risk. Discuss with a physician.
• Active cancer: General caution applies to all metabolic peptides; discuss with your oncologist before initiating.
• Gastroparesis / severe gastric motility issues: Cagrilintide slows gastric emptying as part of its mechanism — generally contraindicated in established gastroparesis.
• Drug interactions: Slowed gastric emptying can affect absorption of oral medications taken at the same time. Time other oral drugs at least 1–2 hours apart from cagrilintide-affected mealtimes if you’re on time-critical oral medications (oral contraceptives, blood pressure meds, etc.).

Comparison and stacking

Cagrilintide alone vs. CagriSema vs. cagri + retatrutide

Approach	Evidence	Expected outcome	Best for
Cagrilintide monotherapy	706 adults, 26 wks, 10.8% wt loss at 4.5mg dose	Modest weight loss, primarily from satiety/portion control	Users who want appetite work but want to avoid the GLP-1 drug class entirely; users on a research-use-only sourcing path who can’t readily access compounded sema or reta
CagriSema (cagri + sema)	3,417 adults, 68 wks, 20.4% wt loss (60% ≥20%; 23% ≥30%)	The strongest published combination; clinically validated; brand-name regulatory path	Users who want the most data-anchored combination available; users targeting body weight loss >20% over a year
Cagri + retatrutide	No published RCT	Mechanistically: amylin (satiety switch) + GLP-1 (appetite thermostat, weaker) + GIP (potent) + glucagon (hepatic fat oxidation) = four pathways instead of two. Real-world outcomes anecdotally strong.	Users already on retatrutide who still experience meaningful food noise; experienced users who understand the speculative-but-mechanistically-sound framing

Practitioner-camp 4:1 reta:cagri stacking ratio (anecdotal)

For retatrutide + cagrilintide users, a 4:1 reta:cagri dose ratio (e.g., 1.0–2.0 mg retatrutide + 0.25 mg cagrilintide weekly) has been reported by creator-tier sources as a practical sweet spot — strong combined effect without over-suppression. This is anecdotal practitioner-camp convention, NOT a published trial protocol. Adopt with that distinction in mind.

Use-case-fit honest framing — when cagrilintide is the right tool vs when it’s the wrong tool

Cagrilintide is at its highest-leverage value for users with strong food noise, persistent appetite-control difficulty, or measurable body-fat loss as the primary goal — the customer profile that explicitly needs the amylin satiety switch turned on hard. For that profile, cagrilintide (alone or stacked on a GLP-1) is a meaningful addition to the toolkit.

For users already at healthy body composition who want milder appetite optimization without engaging the GLP-1 / amylin drug class hard, 5-Amino-1MQ injectable is a defensible alternative. It operates through the NAD+ salvage pathway (NNMT inhibition) rather than the satiety-receptor route — a different mechanism for a different use case. Not better or worse than cagrilintide — different fit for different customer profiles.

The honest customer-segmenting question: “Is the bottleneck food noise / over-eating, or is it metabolism / energy / body-composition optimization?” If food noise → cagrilintide. If metabolism/optimization → 5-Amino-1MQ. Both can have a place in a long-term stack; matching the tool to the actual bottleneck matters more than choosing the strongest available signal.

Cagrilintide vs. Eloralintide

A note for users tracking the amylin-pathway pipeline: eloralintide is a newer selective amylin-receptor agonist also in late-stage trials (Phase 2 published 2025 in Lancet). The class is expanding. Cagrilintide is the most clinically mature amylin-pathway drug; eloralintide is one to watch as the published evidence base develops.

Regulatory status

• Cagrilintide as a standalone product: NOT FDA-approved. Sold by research-use-only verified peptide vendors. Not a legal over-the-counter supplement.
• CagriSema (the combination product): post-REDEFINE 1 + REDEFINE 2 Phase 3 publication (NEJM June 2025), the regulatory pipeline path is clear. Novo Nordisk is pursuing FDA approval; timing not yet finalized as of June 2026. Once approved, CagriSema will be a brand-name pharmaceutical available through standard pharmacy channels.
• The verified-vendor compounded path is the access point until/unless the brand product arrives at acceptable OOP cost. This is the same pattern OHM has covered extensively for retatrutide, semaglutide, and the GLP-1 cluster more broadly — see The Compounding Pharmacy Pathway (503A/503B).

Vendor mapping and commercial layer

Where to buy (OHM-affiliated, verified-COA)

US Pure Peptides is the primary OHM-affiliated route for cagrilintide as of 2026-07-09:

• Product: cagrilintide 10 mg lyophilized vial — uspurepeptides.com/products/cagriniltide-10mg (note: USP URL spells it “cagriniltide” — same compound)
• Coupon: OHM20 for 20% off (vanity link optimalhealthmanifesto.com/uspurepeptides → uspurepeptides.com)
• ISO 17025-accredited third-party COA; US-manufactured in West Palm Beach, FL; free BAC water

BioLongevity Labs is the secondary OHM-affiliated route:

• Product: cagrilintide 5 mg lyophilized vial — biolongevitylabs.com/product/cagrilintide-amylin-analog/
• Coupon: OHM-15 at BioLongevity for 15% off (vanity link optimalhealthmanifesto.com/biolongevity)

Alyve: cagrilintide is NOT in Alyve’s current catalog.

Code-namespace rule

Three codes, three vendors — always name the specific vendor with the code, never write a code bare. For cagrilintide: OHM20 at US Pure Peptides (primary); OHM-15 at BioLongevity (secondary). OHM-15 is shared by Alyve AND BioLongevity — another reason to name the vendor every time.

Why verified vendor matters here

Cagrilintide is in a different regulatory category from most peptides OHM covers. Novo Nordisk is pursuing it through the FDA pharmaceutical approval pathway via CagriSema (the combination product) — which means cagrilintide is NOT on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) docket that’s reviewing seven other peptides for 503A compounding eligibility (see BPC-157: the mainstream skeptical view for the broader PCAC-docket context — BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon). That puts cagrilintide on a more regulatorily mainstream path than the 7-peptide compounding-list crowd — but it also means the brand-name product will arrive with brand-name pricing once approved.

Until then, the verified-vendor / verified-COA framing still matters for the same reason it matters across the catalog: the molecule must actually be the molecule the vendor claims it is (correct sequence, correct purity, no contamination). The OHM editorial position is consistent: the science behind cagrilintide is real and validated; the gray-market supply-chain risk is the actual variable; OHM-verified vendors (US Pure Peptides primary, BioLongevity secondary) handle that variable with independent third-party testing.

Content hooks for OHM coverage

Five angles the OHM content team can run with cagrilintide:

1. “Why you’re still hungry on retatrutide — and the one peptide that fills the gap” — the satiety-switch-vs-appetite-thermostat framing as the lead. Customer-facing intro to cagrilintide; converts the “I’m on retatrutide but still hungry” segment.
2. “REDEFINE 1: the Phase 3 data that just changed weight-loss medicine” — the 20.4% / 60% ≥20% / 23% ≥30% / 88% prediabetes-resolution numbers as the lead. Anchors OHM’s credibility as a source that knows the actual RCT base.
3. “The protein-priority warning every cagrilintide user needs to read” — the muscle-preservation / “skinny fat” failure mode as the lead. The single most important safety message in the metabolic-cluster content space; foundation-first OHM editorial voice.
4. “Cagrilintide vs. CagriSema vs. cagri + reta: what’s actually been studied” — honest-tier framing on the cagri + reta stacking case. Captures the “is this safe to stack” customer question without overclaiming or underclaiming.
5. “Two pathways, two parts of the brain: how cagrilintide pairs with any GLP-1 drug” — the mechanism story (hypothalamus thermostat vs brainstem switch) as the lead. Reusable across customer-facing pieces on any cagri stack.

Cross-references

In-KB (peptide articles)

• Retatrutide — the primary stacking partner the digest video focuses on; mechanism overlap is zero (cagri = amylin; reta = GLP-1 / GIP / glucagon)
• Semaglutide — the clinically-validated combination partner (CagriSema)
• Tirzepatide — also a viable stacking partner mechanistically (cagri = amylin; tirz = GLP-1 / GIP); no published combination trial yet
• 5-Amino-1MQ — alternative for the optimization-tier user profile (NAD+ salvage pathway; different mechanism, different use-case fit)
• The GLP-1 Pipeline (2026) — landscape article; cagrilintide is one row in the pipeline table; this wiki provides the per-peptide depth
• the metabolic fat-loss peptides — broader metabolic-stack framing
• Building a Fat-Loss Peptide Stack — protocol-construction context; cagrilintide is a candidate adjunct
• Mitochondrial Health Foundations — the foundation article that should sit beneath any metabolic-stack adoption (protein, sleep, exercise, NAD+ for the matrix-layer support)

External anchors — published peer-reviewed papers (7 confirmed as of 2026-06-29)

• Enebo et al. 2021 Lancet (PMID 33894838) — Phase 1b PK/PD/safety of cagrilintide + semaglutide combination (the foundation paper)
• Lau et al. 2021 Lancet 398:2160-2172 (PMID 34798059) — cagrilintide Phase 2 monotherapy dose-finding trial
• Frias et al. 2023 Lancet (PMID 37364590) — Phase 2 CagriSema in type 2 diabetes (the bridge paper between Phase 2 mono and Phase 3 combination) -(https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) — Phase 3 CagriSema in overweight/obesity (3,417 adults, 68 weeks, 4-arm design) -(https://www.nejm.org/doi/abs/10.1056/NEJMoa2502082) — Phase 3 CagriSema in T2D + overweight/obesity (1,206 adults, 68 weeks)
• Carvas et al. 2025 eBioMedicine (PMC12270663) — mechanism paper identifying AMY1R + AMY3R as cagrilintide-dependent receptors + lean-mass-preservation finding
• Systematic review + meta-analysis (PMC11642503) — efficacy + safety pooled across cagrilintide-alone and CagriSema trials

External anchors — related context

• Coskun et al. 2022 Cell Metabolism (PMID 35985340) — foundational retatrutide pharmacology paper (verified the corrected receptor-potency profile)
• BioLongevity Labs cagrilintide product page -(https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html)
• ACC summary of REDEFINE 1 + REDEFINE 2

Registered ongoing trials worth watching

• NCT07527195 — Muscle health study (CagriSema, cagrilintide, semaglutide) — completion June 2028
• NCT07607587 — Cagrilintide tolerability in GLP-1-RA-intolerant patients
• NCT06403761 — CagriSema, sema, cagri insulin-effects mechanism in T2D
• NCT07220642 — Longer-term cagrilintide monotherapy in obesity
• NCT07220759 — Cagrilintide monotherapy in T2D + overweight/obesity

Source digests

• Josh Holyfield 12:10 YouTube on cagrilintide mechanism + cagri+reta stacking case. Original source for the wiki’s mechanism + stacking framing (REWIND→REDEFINE trial name correction; retatrutide GCG potency 0.3× not “full” correction; vendor confirmations).
• Taylor Williams 21-min personal-experience review. Source for the anecdotal mood-change cluster framing + the gas side-effect addition + the low-dose responder anecdote + the 4:1 reta:cagri ratio + the use-case-fit framing (with the unverified amylin-serotonin mechanism explicitly tier-flagged, not propagated).
• canonical inventory of all 7 published peer-reviewed cagrilintide papers + all 9 registered ClinicalTrials.gov entries as of 2026-06-29. First research-* aggregation file in the peptides KB raw/. Source for the full 4-arm REDEFINE 1 breakdown, the REDEFINE 2 full details, the Enebo 2021 Phase 1b addition, the Frias 2023 Phase 2 T2D bridge paper, the Carvas 2025 mechanism paper findings, the systematic review citation, and the ongoing-studies inventory.

---

The bottom line on cagrilintide: it’s an amylin analog that targets a completely separate brain pathway from the GLP-1 / GIP / glucagon family. The Phase 3 evidence (REDEFINE 1 NEJM 2025) is strong — substantially stronger than most peptides OHM covers. Cagri + semaglutide (CagriSema) is the clinically validated combination; cagri + retatrutide is mechanistically defensible but clinically untested — adopt with that distinction in mind. Protein priority + resistance training is non-negotiable on any cagrilintide protocol (with or without a GLP-1 drug stacked on top). Verified-vendor sourcing — US Pure Peptides (code OHM20, 20% off, primary) or BioLongevity (code OHM-15, 15% off, secondary) — until the brand-name CagriSema arrives at acceptable OOP cost.